Arch Therapeutics (OTCMKTS:ARTH) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Thursday.
According to Zacks, “Arch Therapeutics, Inc. is a medical device company. It develops products that make surgery and interventional care faster and safer by using an approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The Company’s lead product candidate includes AC5 (TM), a biocompatible synthetic peptide, to achieve hemostasis in minimally invasive and open surgical procedures. Arch Therapeutics, Inc. is headquartered in Wellesley, Massachusetts. “
Several other equities analysts have also recently issued reports on the stock. LADENBURG THALM/SH SH assumed coverage on shares of Arch Therapeutics in a research note on Wednesday, September 12th. They issued a “buy” rating for the company. HC Wainwright set a $3.00 target price on shares of Arch Therapeutics and gave the company a “buy” rating in a research note on Monday, October 8th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $1.75.
Arch Therapeutics Company Profile
Arch Therapeutics, Inc, operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures.
Further Reading: Cash Flow
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.